DOW JONES22,327.48+690.70 3.19%
S&P 5002,626.65+85.18 3.35%
NASDAQ7,774.15+271.77 3.62%

Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $125

Morgan Stanley maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $120 to $125.

Benzinga · 03/03/2020 13:12

Morgan Stanley maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $120 to $125.